Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated in phase 2 study in anti-neutrophil cytoplasmic antibody ("ANCA")-associated vasculitis.
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
July 19, 2023
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imlifidase,Immunoglobulin
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Idefirix (Imlifidase), IgG degrader enzyme in combination with Immunoglobulin antibodies. It is being evaluating in the Phase II clinical trial studies for the treatment of Guillain-Barre Syndrome.
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : Imlifidase,Immunoglobulin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As a comparison the overall renal survival over 12 trials has been reported to be 26% with current Standard of Care (SoC)1. This positive outcome served as Proof of Concept (PoC) for the potential of imlifidase to treat IgG-mediated serious autoimmune di...
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobitolimod
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
Product Name : Kappaproct
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 21, 2021
Lead Product(s) : Cobitolimod
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobitolimod
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InDex Pharmaceuticals Gets Patent for Additional Dims Compounds Granted in Europe
Details : InDex’s Kappaproct is a synthetic oligonucleotides that function as immunomodulatory agents by targeting Toll-like receptor 9 (TLR9). DIMS mimic bacterial DNA, without being harmful, and stimulate immune cells to produce beneficial cytokines.
Product Name : Kappaproct
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 04, 2021
Lead Product(s) : Cobitolimod
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GS-248
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gesynta Pharma’s first-in-class drug candidate GS-248 provides a combination of anti-inflammatory and vasodilatory effects by potently and selectively inhibiting microsomal prostaglandin E synthase-1 (mPGES-1).
Product Name : GS-248
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : GS-248
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Izokibep
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is a multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035.
Product Name : ABY-035
Product Type : Protein
Upfront Cash : Inapplicable
October 11, 2020
Lead Product(s) : Izokibep
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantation.
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeximod
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyxone Revises the Development Plan for Rabeximod
Details : New patent applications have been filed to extend exclusivity on Rabeximod, potentially to 2043. A patent application related to Covid-19 has also been filed.
Product Name : Rob 803
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : Rabeximod
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable